Genus plc (LON:GNS)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX 2,390.00
+6.00 (0.25%)
Nov 4, 2026, 4:48 PM GMT
Genus Revenue
In the fiscal year ending June 30, 2026, Genus had annual revenue of 658.10M GBP, down -2.18%. Genus had revenue of 322.50M in the half year ending June 30, 2026, a decrease of -3.79%. That makes Genus the 8,217th largest company in the world by revenue and 218th in the United Kingdom.
Revenue
658.10M
Revenue Growth
-2.18%
P/S Ratio
2.34
Revenue / Employee
225.30K
Employees
2,921
Market Cap
1.54B
Revenue by Segment
Fiscal year ended Jun 30, 2026 See the full Genus breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 658.10M | -14.70M | -2.18% |
| Jun 30, 2025 | 672.80M | 4.00M | 0.60% |
| Jun 30, 2024 | 668.80M | -20.90M | -3.03% |
| Jun 30, 2023 | 689.70M | 96.30M | 16.23% |
| Jun 30, 2022 | 593.40M | 19.10M | 3.33% |
| Jun 30, 2021 | 574.30M | 22.90M | 4.15% |
| Jun 30, 2020 | 551.40M | 62.90M | 12.88% |
| Jun 30, 2019 | 488.50M | 18.20M | 3.87% |
| Jun 30, 2018 | 470.30M | 11.20M | 2.44% |
| Jun 30, 2017 | 459.10M | 70.80M | 18.23% |
| Jun 30, 2016 | 388.30M | -10.20M | -2.56% |
| Jun 30, 2015 | 398.50M | 26.30M | 7.07% |
| Jun 30, 2014 | 372.20M | 26.90M | 7.79% |
| Jun 30, 2013 | 345.30M | 3.50M | 1.02% |
| Jun 30, 2012 | 341.80M | 31.90M | 10.29% |
| Jun 30, 2011 | 309.90M | 24.60M | 8.62% |
| Jun 30, 2010 | 285.30M | 4.90M | 1.75% |
| Jun 30, 2009 | 280.40M | 33.30M | 13.48% |
| Jun 30, 2008 | 247.10M | 13.30M | 5.69% |
| Jun 30, 2007 | 233.80M | 5.99M | 2.63% |
| Mar 31, 2005 | 227.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Oxford Nanopore Technologies | 235.00M |
| Oxford Biomedica | 175.36M |
| Bioventix | 12.97M |
| PureTech Health | 4.80M |
| Scancell Holdings | 4.71M |
| Ondine Biomedical | 1.53M |
| Faron Pharmaceuticals Oy | 1.14M |
| 4basebio | 781.00K |
Genus News
- 26 days ago - Panama earthquake: NEMA, GNS assessing whether tsunami could affect NZ - NZ Herald
- 7 weeks ago - Genus H2 Earnings Call Highlights - MarketBeat
- 7 weeks ago - Genus Earnings Call Transcript: H2 2026 - Transcripts
- 7 weeks ago - Genus Annual report: H2 2026 - Filings
- 7 weeks ago - Genus Slides: H2 2026 - Filings
- 7 weeks ago - Genus Annual report: H2 2026 - Filings
- 3 months ago - Genus upgraded to Buy from Hold at Kepler Cheuvreux - TheFly
- 3 months ago - Genus Earnings release: Trading update - Filings